HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graves, P. R. Articles by Piwnica-Worms, H. Search for Related Content PubMed PubMed Citation Articles by Graves, P. R. Articles by Piwnica-Worms, H. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 8, 5600-5605, February 25, 2000

The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01^*

Paul R. Graves, Lijia Yu^§, Julie K. Schwarz, Janis Gales, Edward A. Sausville^¶, Patrick M. O'Connor^§, and Helen Piwnica-Worms^**

From the  Department of Cell Biology and Physiology, ^** Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri 63110, the ^§ Laboratory of Molecular Pharmacology, Division of Basic Sciences, and the ^¶ Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, National Institutes of Health, Bethesda, Maryland 20892

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

A checkpoint operating in the G₂ phase of the cell cycle prevents entry into mitosis in the presence of DNA damage. UCN-01, a protein kinase inhibitor currently undergoing clinical trials for cancer treatment, abrogates G₂ checkpoint function and sensitizes p53-defective cancer cells to DNA-damaging agents. In most species, the G₂ checkpoint prevents the Cdc25 phosphatase from removing inhibitory phosphate groups from the mitosis-promoting kinase Cdc2. This is accomplished by maintaining Cdc25 in a phosphorylated form that binds 14-3-3 proteins. The checkpoint kinases, Chk1 and Cds1, are proposed to regulate the interactions between human Cdc25C and 14-3-3 proteins by phosphorylating Cdc25C on serine 216. 14-3-3 proteins, in turn, function to keep Cdc25C out of the nucleus. Here we report that UCN-01 caused loss of both serine 216 phosphorylation and 14-3-3 binding to Cdc25C in DNA-damaged cells. In addition, UCN-01 potently inhibited the ability of Chk1 to phosphorylate Cdc25C in vitro. In contrast, Cds1 was refractory to inhibition by UCN-01 in vitro, and Cds1 was still phosphorylated in irradiated cells treated with UCN-01. Thus, neither Cds1 nor kinases upstream of Cds1, such as ataxia telangiectasia-mutated, are targets of UCN-01 action in vivo. Taken together our results identify the Chk1 kinase and the Cdc25C pathway as potential targets of G₂ checkpoint abrogation by UCN-01.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

UCN-01 is a protein kinase inhibitor currently undergoing clinical trials for cancer treatment. UCN-01 potentiates the cytotoxicity of a variety of anticancer agents including cisplatin, camptothecin, and ionizing radiation (1-3). These latter findings have encouraged the investigation of UCN-01 in combination stratagems for cancer treatment. A potential mechanism underlying the sensitization of cancer cells to DNA-damaging agents is the abrogation of cell cycle checkpoint function in the G₂ phase of the cell cycle (1, 2). Interestingly, abrogation of the G₂ checkpoint appears to occur preferentially in cancer cells with defective p53 tumor suppressor function (1). UCN-01-induced G₂ checkpoint abrogation has previously been shown to occur through a Cdc2-dependent pathway resulting in premature activation of this mitosis-promoting kinase in DNA-damaged cells (1, 4). The molecular mechanism(s) underlying Cdc2 activation and G₂ checkpoint abrogation by UCN-01 are not known.

Cdc2 is subject to multiple levels of regulation including periodic association with the B-type cyclins, reversible phosphorylation, and intracellular compartmentalization (for reviews see Refs. 5-7). Phosphorylation of human Cdc2 occurs on three regulatory sites as follows: threonine 14, tyrosine 15, and threonine 161 (8-11). Cdc2 is retained in an inactive state throughout the S and G₂ phases of the cell cycle by Thr-14 and Tyr-15 phosphorylation (11-16). The Wee1 protein kinase phosphorylates Cdc2 on tyrosine 15, whereas the Myt1 protein kinase phosphorylates Cdc2 on both threonine 14 and tyrosine 15 (16-26). In late G₂, the Cdc25C phosphatase dephosphorylates Cdc2 on both Thr-14 and Tyr-15, leading to the activation of Cdc2-cyclin B1 complexes (27-31). In addition to cyclin binding and reversible phosphorylation, Cdc2 is also regulated at the level of intracellular compartmentalization. Throughout interphase, Cdc2-cyclin B1 complexes shuttle between the nucleus and the cytoplasm (32-34). The apparent cytoplasmic localization of Cdc2-cyclin B1 complexes (35) is due to a nuclear export signal (NES)¹ in cyclin B1 which facilitates rapid export of Cdc2-cyclin B1 complexes from the nucleus. Phosphorylation of the NES in late prophase is proposed to block the nuclear export of cyclin B1 by interfering with the binding of the nuclear export receptor CRM1 leading to the nuclear accumulation of Cdc2-cyclin B1 complexes (33, 36). Thus, entry into mitosis requires not only the activation of Cdc2 by Cdc25C but also the accumulation of active Cdc2-cyclin B1 complexes in the nucleus. Because UCN-01 disrupts G₂ checkpoint function by prematurely activating Cdc2, UCN-01 could theoretically interfere with one or more of the Cdc2 regulatory pathways described above.

We undertook a comprehensive study to examine the effects of UCN-01 on proteins that directly regulate Cdc2, including Wee1, Myt1, and Cdc25C. Previously we reported that UCN-01 abrogated G₂ arrest following DNA damage through a Cdc2-dependent pathway but did not involve direct inhibition of the Wee1 kinase (4). Indeed, concentrations of UCN-01 as high as 1 µM did not affect the ability of Wee1 to phosphorylate Cdc2-cyclin B1 complexes in vitro. In the present study, we investigated effects of UCN-01 on a second Cdc2-inhibitory kinase, Myt1, and on the Cdc25C regulatory pathway.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Chemicals and Reagents-- UCN-01 (NSC 638850) was provided by Jill Johnson (Drug Synthesis and Chemistry Branch, NCI, National Institutes of Health). Nocodazole (Aldrich) was prepared in dimethyl sulfoxide.

Mitotic Index-- HeLa cells were harvested by trypsinization and then collected by centrifugation (1000 × g for 5 min). Following washing with PBS, cells were resuspended in 75 mM KCl for 10 min. Cells were pelleted and then fixed in acetic acid/methanol (1:3 v/v). Fixed cells were stained with 0.1 µg/ml 4,6-diamidino-2-phenylindole for 5 min, allowed to air-dry, and observed by light microscopy. A minimum of 500 cells were counted for each sample.

Cloning of Human Cds1-- HeLa total RNA was isolated using the TRIzol reagent RNA isolation kit (Life Technologies, Inc.) followed by treatment with RNase-free DNase. First strand cDNA was prepared using 1st Strand cDNA Synthesis Kit from CLONTECH. A mixture of oligo(dT) and random hexamers was used to prime the reverse transcriptase reaction. Degenerate primers were designed to conserved motifs in the forkhead-associated and kinase domains of Cds1Sp, Rad53Sc, Dun1Sc, an ovarian-specific Ser/Thr kinase from Drosophila present in GenBank^TM (accession number 1848279), and a mouse EST clone (accession number AA762997). Primers 5'-AGTAGTAATGGTAC(C/T) TTTATAAAT) and 5'-TTC(A/T)GG(C/T)TTNA(A/T/G)(A/G)TCNC(T/G)(A/G)TG) were used in a PCR reaction with template prepared from HeLa cell total RNA. PCR products were cloned into the TA vector (InVitrogen) and sequenced.

Full-length huCds1 cDNA was generated by 5'- and 3'-rapid amplification of cDNA ends (RACE) using Human HeLa Marathon Ready cDNA (CLONTECH). Briefly, 2 sets each of forward and reverse primers were designed by selecting-GC rich regions within the 570-base pair PCR product of huCds1 (forward primers, 5'-GAAGTGGTGCCTGTGGAGAGGTAA and 5'-CAGCAAGAGAGGCAGACCCAGCTCTCAA, and reverse primers, 5'-GAGAGCTGGGTCTGCCTCTCTTGCTGAA and 5'-GCTTGCAGGTAGCTTCTT TCAGGCGTTT). These gene-specific primers were used in combination with the linker primer AP-1 to amplify 5' and 3' sequences of huCds1 using a step-down PCR technique. Both 5'- and 3'-RACE reactions of huCds1 yielded single fragments (~1.0 kilobase pair 5' and ~1.2 kilobase pairs 3'). These PCR fragments were cloned into the TA vector and sequenced. Sequence data were used to design new primers to amplify the full-length huCds1 cDNA. Full-length huCds1 cDNA was re-amplified from the HeLa library using the Advantage High Fidelity Polymerase Mix (CLONTECH) and cloned into the TA vector. All PCR products were confirmed by DNA sequencing.

Plasmids-- The coding sequence of full-length huCds1 was amplified by PCR using the following two primers: 5'-CCCGAATTCCATATGTCTCGGGAGTCGGATGTTG (NdeI primer) and 5'-ATAGAATTCCTCGAGTCACAACACAGCAGCACACAC (EcoRI/XhoI primer). The PCR product was ligated to the TA cloning vector, and the resulting plasmid pTA-huCds1 was digested with NdeI and EcoRI. The fragment encoding huCds1 was inserted into the corresponding sites of pGEX2TN to create pGEX2TN-huCds1. pTA-huCds1 was digested with NdeI and XhoI and cloned into the corresponding sites of pET15b to generate pET15b-huCds1. pGEX2TN-huCds1 was digested with XbaI and EcoRI, and the fragment encoding huCds1 was cloned into the StuI site of pFASTBAC to create pFASTBAC-huCds1. Recombinant baculoviruses were generated using the BAC-TO-BAC Baculovirus Expression System (Life Technologies, Inc.) and protocols suggested by the manufacturer. Wild-type human Cdc25C and Cdc25C(S216A) were isolated from pGEX-2T and pGEX-2TB, respectively, by digestion with BamHI and cloned into the BamHI site of pEGFPC-1 to create pEGFP-Cdc25C and pEGFP-Cdc25C(S216A).

Protein Kinase Assays-- GST-Chk1, GST-Cds1, His-Myt1, GST-Cdc25C-motif, and GST-cyclin B1/Cdc2(K/R) were isolated from insect cells or bacteria as described previously (4, 16, 23, 37). His-Myt1 kinase reactions were carried out with GST-cyclin B1/Cdc2(K/R) in 40 µl of kinase reaction buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 10 µM cold ATP, and 10 µCi of [-³²P]ATP (3000 Ci mmol¹; NEN Life Science Products) for 10 min at 30 °C. Reactions were terminated by adding an equal volume of 2× SDS sample loading buffer and boiling for 5 min before being loaded onto 10% SDS-polyacrylamide gels. Following autoradiography kinase reactions were quantified on a PhosphorImager (Molecular Dynamics).

GST-Chk1 and GST-Cds1 kinase reactions were performed in 50 µl of kinase reaction buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 1 mM DTT, 50 µM cold ATP, 10 µCi of [-³²P]ATP (3000 Ci mmol¹; NEN Life Science Products), and 5 µg GST-Cdc25C-motif for 10 min at 30 °C. Radiolabeled GST-Cdc25C-motif was excised and radioactivity quantitated in a scintillation counter.

Effect of UCN-01 on Cdc25C Serine 216 Phosphorylation and 14-3-3 Interactions-- We used either normal HeLa cells or HeLa cells expressing an inducible human Cdc25C transgene (37) to assess the action of UCN-01 on Cdc25C-serine 216 phosphorylation and 14-3-3 interaction. To monitor 14-3-3 association, we induced Cdc25C transgene expression by removal of tetracycline (37). Cdc25C-expressing cells were then treated with 6 Gy of gamma rays and allowed to arrest in G₂ for 12 h in the presence of nocodazole (0.15 µg/ml). Cells were then treated with or without UCN-01 (300 nM) and, at different times thereafter, were harvested and lysed in mammalian cell lysis buffer (50 mM Tris-HCl, pH 8.0, 2 mM DTT, 5 mM EDTA, 0.5% Nonidet P-40, 150 mM sodium chloride, 1 µM microcystin, 1 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl fluoride, 0.15 units/ml aprotinin, 20 mM leupeptin, and 20 mM pepstatin). For normal HeLa cells, total cell lysates were resolved on an 8% SDS-polyacrylamide gel and immunoblotted with the Cdc25C monoclonal antibody (174-E10-3) (37). Cdc25C immunoprecipitations were performed from Cdc25C-overexpressing cells with the same antibody, and the Cdc25C-immune complexes were split and samples resolved on either 8 or 12% SDS-polyacrylamide gels for immunoblotting with Cdc25C (174-E10-3) or 14-3-3 (K-19, Santa Cruz Biotechnology) antibodies, respectively. Cdc2 and cyclin B1 immunoblotting of total cell lysates was performed using the Cdc2 antibody (SC-54) and cyclin B1 antibody (SC-245) (Santa Cruz Biotechnology). Bound primary antibodies were detected using the ECL (Amersham Pharmacia Biotech) detection system.

Effect of UCN-01 on Cds1 Phosphorylation in Response to DNA Damage-- HeLa cells were treated with different concentrations of UCN-01 for 1 h before subjecting them to 0, 5, 10, or 20 Gy of gamma rays. At 2 h post-irradiation, cells were harvested and lysed in mammalian cell lysis buffer, and Cds1 was immunoprecipitated with an affinity purified huCds1 antibody. Cds1 immunoprecipitates were resolved on a 7% SDS-polyacrylamide gel and immunoblotted with the Cds1 affinity purified antibody.

Generation and Purification of Human Cds1 Antibody-- BL21 cells were transformed with pET15b-huCds1. Cultures (1 liter) were grown at 30 °C to an A₆₀₀ of 0.5, and isopropyl-1-thio--D-galactopyranoside was added to a final concentration of 0.5 mM. After growing for an additional 4 h at 30 °C, cells were pelleted by centrifugation. Cell pellets were washed with PBS and resuspended in 40 ml of His lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EGTA, 0.5% Nonidet P-40, 1 mg/ml lysozyme) supplemented with protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 0.15 units/ml aprotinin, 20 µM leupeptin, 20 µM pepstatin). After rocking at 4 °C for 15 min, cells were lysed by sonication (50% duty for 15 bursts). The lysate was clarified by centrifugation (10,000 × g for 15 min at 4 °C) and mixed with 2 ml of packed Ni²⁺-NTA-agarose (Qiagen) for 1 h at 4 °C. The beads were washed 3 times with 10 ml of His wash buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EGTA, 0.5% Nonidet P-40) and transferred to a Bio-Rad disposable column. Protein was eluted with elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 100 mM imidazole, 1 mM DTT, 0.1% Nonidet P-40), and purified His-huCds1 protein was injected into New Zealand White rabbits. To purify antibodies specific for huCds1, GST-huCds1 was coupled to Affi-Gel 10 (Bio-Rad) according to the manufacturer's instructions. After flowing huCds1 antiserum over the column and washing, antibodies were eluted with 0.1 M glycine, pH 2.8, and immediately neutralized with 1 M Tris, pH 8.0.

Effects of UCN-01 on the Localization of Cdc25C-- HeLa cells were grown on 12-mm glass coverslips and transfected with the plasmids pEGFP-Cdc25C or pEGFP-Cdc25C(S216A) using 20 µg/100-mm dish and the calcium phosphate transfection system according to the manufacturer's instructions (Life Technologies, Inc.). At 24 h post-transfection, cells were fixed with 2% paraformaldehyde in PBS. After washing 3 times in PBS, cells were mounted on slides using the Prolong Antifade kit (Molecular Probes, Eugene OR). Cells were viewed using a confocal laser microscope (MRC 1024, Bio-Rad). In some cases, 300 nM UCN-01 was added during the last 2 h of the transfection.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Myt1 Is Poorly Inhibited by UCN-01 in Vitro-- Because UCN-01 is a protein kinase inhibitor, we first investigated whether UCN-01 was promoting mitotic entry in DNA-damaged cells through direct inhibition of the Cdc2-inhibitory kinase, Myt1 (25, 26, 38, 39). We assayed purified Myt1 in vitro in the presence of UCN-01 (Fig. 1A) and found that Myt1 was only weakly inhibited by UCN-01. Furthermore, the concentration of UCN-01 required to inhibit Myt1 activity by 50% (IC₅₀ ~250 nM) was significantly higher than that required to abrogate G₂ arrest following gamma irradiation of HeLa cells (IC₅₀ ~15-20 nM) (Fig. 1B). Taken together, these and previously published (4) results suggested that Wee1 and Myt1 were not the primary targets through which UCN-01 abrogated DNA-damaged-induced G₂ arrest.

View larger version (11K): [in this window] [in a new window]   Fig. 1.   Effect of UCN-01 on Myt1 kinase activity in vitro and on -ray-induced G2 arrest in HeLa cells. A, His-Myt1 was purified from insect cells and incubated in a kinase reaction that contained varying concentrations of UCN-01 and an inactive version of Cdc2 (K33R) complexed with GST-cyclin B1 as a substrate. Following autoradiography, kinase reactions were quantified by determining the amount of radiolabel incorporated into the Cdc2(K/R) band using a PhosphorImager (Molecular Dynamics). B, HeLa cells were incubated for 12 h following 6 Gy of gamma rays in the presence of 0.15 µg/ml nocodazole to trap any cells that entered mitosis. UCN-01 was then added to the culture, and cells were incubated for an additional 8 h to allow for mitotic entry before harvesting and performing mitotic index measurements. The dotted line at 100% represents the normalized percent of cells that accumulated in mitosis upon incubation with nocodazole alone for 20 h (~80% of total culture). The dotted line at 0% represents the normalized percent of cells that accumulated in mitosis following irradiation and incubation with nocodazole (~11% of total culture).

The Cdc25C Regulatory Pathway Is Inhibited by UCN-01 in Vivo-- We next examined whether UCN-01 targeted the Cdc25C regulatory pathway. Cdc25C is negatively regulated by phosphorylation of serine 216 throughout interphase and upon G₂ checkpoint activation (37). During interphase, Cdc25C migrates in SDS gels as two distinct electrophoretic forms, a slower migrating serine 216-phosphorylated form (species b, see Fig. 2A) that binds 14-3-3 proteins (37) and a faster migrating hypophosphorylated form (species a). In mitosis, Cdc25C becomes hyperphosphorylated which reduces its electrophoretic mobility further (species c) (37, 40, 41). Throughout interphase and in the presence of unreplicated or damaged DNA, Cdc25C is phosphorylated on serine 216 and bound to 14-3-3 proteins (37). To determine whether UCN-01 treatment disrupted the Cdc25C regulatory pathway, HeLa cells induced to express Cdc25C (37) were subjected to gamma irradiation and then incubated with or without UCN-01 in the presence of nocodazole to trap any cells entering into mitosis (Fig. 2A). In the absence of UCN-01, Cdc25C was found to be predominantly in the serine 216-phosphorylated form (species b) and bound to 14-3-3 proteins. Mitotic index measurements demonstrated that cells maintained their G₂ cell arrest under these conditions indicative of an intact checkpoint response. In contrast, UCN-01 addition caused the loss of Cdc25C-serine 216 phosphorylation (within 1 h) and the Cdc25C-14-3-3 complex disassembled. These events preceded Cdc2 dephosphorylation and entry of cells into mitosis at which time Cdc25C became hyperphosphorylated (species c).

View larger version (33K): [in this window] [in a new window]   Fig. 2.   Effects of UCN-01 on the Cdc25C regulatory pathway. A, HeLa cells induced to express Cdc25C from a stable transgene were arrested in G2 phase by irradiation with 6 Gy of -irradiation. Nocodazole (0.15 µg/ml) was added to trap any cells that entered mitosis following addition of UCN-01 (300 nM). At different times following UCN-01 addition, cells were harvested, and lysates were either resolved directly on SDS gels or were first subjected to immunoprecipitation using a Cdc25C monoclonal antibody (174-E10-3). Cdc25C-immune complexes were split in two, and samples were resolved on SDS-polyacrylamide gels for immunoblotting with Cdc25C (174-E10-3) or 14-3-3 (K-19, Santa Cruz Biotechnology) antibodies, respectively. A Western blot shows that Cdc25C migrated in SDS gels as a hypophosphorylated species (form a), a serine 216-phosphorylated species (form b), or as a hyperphosphorylated species (form c). Cdc2 also migrates as three distinct bands in SDS gels, the slower migrating forms indicative of inactive Cdc2 phosphorylated on threonine 14 and/or tyrosine 15 (66). Also shown for each sample is the co-precipitation of 14-3-3 proteins and the percent of cells in mitosis (mitotic index (MI)). B, HeLa cells were transfected with plasmids encoding pEGFP-Cdc25C (left panels) or pEGFP-Cdc25C(S216A) (right panels) and left untreated (top panels) or treated with 300 nM UCN-01 for 2 h prior to fixation (bottom panels). Cells were fixed and GFP fluorescence was visualized by confocal microscopy. C, asynchronously growing HeLa cells were incubated with the indicated concentrations of UCN-01 for 2 h before harvesting. Total lysates were resolved on SDS gels and immunoblotted with a Cdc25C monoclonal antibody (174-E10-3). Cdc25C migrated as a serine 216-phosphorylated species (form b) or as a serine 216-unphosphorylated species (form a).

UCN-01 Modulates the Localization of Cdc25C in Vivo-- We next examined the effect of UCN-01 treatment on the intracellular localization of Cdc25C because 14-3-3 binding has been shown to contribute to the nuclear exclusion of Cdc25 (42-46). Cdc25C and a mutant of Cdc25C that cannot bind to 14-3-3 proteins (Cdc25C(S216A)) (37) were tagged with the green fluorescent protein (GFP) and transiently expressed in HeLa cells (Fig. 2B). In the absence of UCN-01, GFP-tagged wild-type Cdc25C localized exclusively to the cytoplasm (top left panel), whereas both nuclear and cytoplasmic fluorescence was detected in cells expressing GFP-tagged Cdc25C(S216A) (top right panel). These findings are consistent with those reported by Dalal et al. (46). A large fraction of Cdc25C(S216A), the 14-3-3 binding mutant of Cdc25C, was detected in the cytoplasm indicating that 14-3-3 binding is not the sole determinant regulating Cdc25C intracellular compartmentalization. A nuclear export sequence in Cdc25C likely contributes to the prominent cytoplasmic staining of both Cdc25C and of the Cdc25C(S216A) mutant protein.² Because UCN-01 treatment causes loss of 14-3-3 binding to Cdc25C, the fluorescence pattern of wild-type Cdc25C in the presence of UCN-01 was predicted to be similar to that of Cdc25C(S216A). This was indeed the case as GFP-Cdc25C was detected in both the nucleus and the cytoplasm of cells treated with UCN-01 (bottom left panel). The prominent cytoplasmic staining of Cdc25C in the presence of UCN-01 indicates that UCN-01 does not perturb Cdc25C NES function. In addition, UCN-01 treatment did not detectably alter the localization of Cdc25C(S216A) (bottom right panel). Although UCN-01-treated cells showed only modest nuclear accumulation of Cdc25C, this may be sufficient to initiate the autocatalytic loop that has been described for Cdc2 activation and mitotic entry (41, 47, 48) (see "Discussion").

To determine the concentration of UCN-01 where loss of Cdc25C-serine 216 phosphorylation could first be observed, HeLa cells were incubated with varying concentrations of UCN-01, and the electrophoretic mobility of Cdc25C was monitored by immunoblotting (Fig. 2C). Serine 216 dephosphorylation was monitored by observing the accumulation of species a after 2 h of incubation with UCN-01. We found that Cdc25C was dephosphorylated on serine 216, as indicated by an increase of band a, with as little as 10 nM UCN-01. Although the majority of Cdc25C was not dephosphorylated until UCN-01 reached 300 nM, it is conceivable that a small amount of dephosphorylated Cdc25C may be able to initiate the autocatalytic loop and contribute to bypass of the arrest.

UCN-01 Potently Inhibits the Kinase Activity of Chk1 but Not Cds1 in Vitro-- We and others (37, 49-53) have previously demonstrated that the Chk1 and Cds1 protein kinases phosphorylate human Cdc25C on serine 216 in vitro. We performed kinase assays to assess the inhibitory activity of UCN-01 on the human Chk1 and Cds1 protein kinases (Fig. 3A). We used a region of Cdc25C (amino acids 200-256) encompassing the site where Chk1 and Cds1 phosphorylate Cdc25C (serine 216) as a substrate. UCN-01 was a potent inhibitor of Chk1 autophosphorylation (data not shown) and Cdc25C-serine 216 phosphorylation with IC₅₀ values of ~25 nM (Fig. 3A). Collectively, these data are consistent with Chk1 being a target of UCN-01 action in vivo. In contrast, Cds1 retained 84% of its activity in the presence of 1 µM UCN-01 indicating that Cds1 is not likely to be a direct target of UCN-01 action (Fig. 3A). Cds1 becomes phosphorylated and activated in response to DNA damage in an ATM-dependent manner (50-53). We next asked whether UCN-01 interfered with the DNA damage-induced phosphorylation of Cds1 in vivo. This phosphorylation is dependent upon ATM function and reflects activation of Cds1 in vivo following DNA damage. HeLa cells incubated with UCN-01 were irradiated, and the phosphorylation status of Cds1 was determined by monitoring the mobility of Cds1 on SDS gels. UCN-01 treatment had no effect on the ability of Cds1 to become phosphorylated in response to DNA damage (Fig. 3B, top panel) even with concentrations of UCN-01 that resulted in significant loss of Cdc25C-serine 216 phosphorylation (bottom panel). Although the results shown in Fig. 3B were obtained using 20 Gy of -irradiation, similar results were obtained with 5 and 10 Gy (data not shown). Because the mobility shift of Cds1 observed in the presence of DNA damage is dependent on a functional ATM protein, we infer that UCN-01 does not significantly inhibit the activity of ATM in vivo.

View larger version (22K): [in this window] [in a new window]   Fig. 3.   Effect of UCN-01 on the activity of the human Chk1 and Cds1 protein kinases. A, GST-huChk1 and GST-huCds1 were purified from insect cells and incubated in kinase reactions containing GST-Cdc25C motif and varying concentrations of UCN-01. Data shown are representative of 3 independent experiments. Filled triangles, GST-huCds1; filled diamonds, GST-huChk1. B, asynchronously growing HeLa cells were treated with the indicated concentrations of UCN-01 for 1 h and then either mock-irradiated or irradiated with 20 Gy of -irradiation. Cell lysates were prepared and resolved directly by SDS-polyacrylamide gel electrophoresis for Cdc25C immunoblotting (lower panel) or were incubated with affinity purified anti-huCds1 antibody prior to SDS-polyacrylamide gel electrophoresis and immunoblotting (upper panel). Lane 1, mock-irradiated HeLa cells; lane 2, irradiated HeLa cells; lane 3, irradiated HeLa cells plus 300 nM UCN-01; lane 4 irradiated HeLa cells plus 1 µM UCN-01.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The G₂ DNA damage checkpoint operates at least in part by preventing the Cdc25 phosphatase from activating the Cdc2 kinase. This is accomplished by maintaining Cdc25 in a phosphorylated form that binds 14-3-3 proteins (37, 43, 54, 55). The binding of 14-3-3 proteins prevents Cdc25 from accumulating in the nucleus (42-46), and this presumably prevents Cdc2 from being activated in the nucleus as it shuttles between the cytoplasm and the nucleus during the G₂ checkpoint response. Our results establish an important link between UCN-01, an agent undergoing clinical trials for cancer treatment, and the Cdc25C regulatory pathway (Fig. 4). We report that treatment of cells with UCN-01 causes Cdc25C to become dephosphorylated on serine 216. Consistent with this phosphorylation site being important for checkpoint fidelity, mutation of serine 216 to alanine attenuates checkpoint control in human cells (37). The Chk1 protein kinase phosphorylates Cdc25C on serine 216 (49), and this kinase is particularly sensitive to inhibition by UCN-01. These results provide a formal link between the G₂ checkpoint abrogating activity of UCN-01, the Cdc25C regulatory pathway, and the Chk1 protein kinase (Fig. 4).

View larger version (14K): [in this window] [in a new window]   Fig. 4.   Model of the DNA damage checkpoint. During the cellular response to DNA damage, Cdc2 is maintained in an inactive state through phosphorylation by the Wee1 and Myt1 protein kinases. The DNA damage checkpoint operates, in part, by preventing the Cdc25C phosphatase from dephosphorylating Cdc2 on the inhibitory sites. The Cds1 and Chk1 protein kinases become phosphorylated in response to DNA damage and phosphorylate Cdc25C on a negative regulatory site in vitro. Chk1 also phosphorylates the Wee1 protein kinase in vitro. Although the pathway upstream of Chk1 is not known and could still involve ATM, the DNA damage-induced modification of Cds1 has been shown to require ATM. UCN-01, a potent abrogator of the DNA damage checkpoint, inhibits Chk1 but not Cds1 or ATM. Inactivation of Chk1 by UCN-01 may cause checkpoint abrogation by allowing Cdc25C to accumulate in the nucleus and thereby activate Cdc2.

Although a pivotal role for Chk1 in controlling the DNA damage G₂ checkpoint has been demonstrated in fission yeast (56, 57), a similar role for the human Chk1 kinase has not been demonstrated. Interestingly, Chk1 appears to play a supportive role to the Cds1 kinase in regulating the DNA replication checkpoint in fission yeast (54, 58, 59). Both Chk1 and Cds1 phosphorylate fission yeast Cdc25 at sites that enable 14-3-3 protein binding, and mutation of these sites in Cdc25 disrupts both the DNA replication and damage checkpoints in fission yeast (43, 54). Consistent with the fission yeast findings, the human Chk1 and Cds1 protein kinases phosphorylate Cdc25C on serine 216, the 14-3-3-binding site (49-53). Although the human Chk1 and Cds1 protein kinases phosphorylate Cdc25C on serine 216 in vitro, there is no functional data to demonstrate that these kinases function to phosphorylate human Cdc25C in vivo. Our results indicate that Chk1 may indeed function as a Cdc25C kinase in vivo. In contrast, the finding that the Cdc25C regulatory pathway is disrupted in UCN-01-treated cells, yet the Cds1 pathway is intact, may indicate that Cds1 does not serve as a major Cdc25C kinase in DNA-damaged cells (Fig. 4).

Entry into mitosis requires both the activation of Cdc2 by Cdc25C and the accumulation of active Cdc2 within the nucleus of the cell. Although it is unclear how the interactions between Cdc2 and Cdc25 are initiated, one requirement may be the dephosphorylation of Cdc25C on serine 216 and subsequent loss of 14-3-3 binding. Loss of 14-3-3 binding allows Cdc25C to move into the nucleus more efficiently and in turn enhances the accessibility of Cdc25C to nuclear pools of Cdc2-cyclin B1. Once a small amount of Cdc2 became activated by Cdc25C, an auto-amplification loop would be initiated whereby activated Cdc2 promotes the activation of Cdc25C which in turn triggers further activation of Cdc2. This pathway coupled to the one that down-regulates the Cdc2 inhibitory kinases provides a mechanism for the rapid amplification of Cdc2 activity observed as cells enter into mitosis (41, 47, 48). Thus, UCN-01 may cause efficient activation of Cdc2 by causing only partial dephosphorylation of Cdc25C on serine 216. Consistent with this hypothesis, at the IC₅₀ of UCN-01 required for abrogating G₂ arrest (15-20 nM), a modest but not complete dephosphorylation of Cdc25C on serine 216 was observed (Fig. 2C).

UCN-01 must affect pathways in addition to the Cdc25C-serine 216 regulatory pathway because the checkpoint abrogation observed after UCN-01 treatment is much more severe than that observed after expression of a 14-3-3-binding mutant of Cdc25C (37). The fact that cells treated with checkpoint abrogators like UCN-01 cause premature entry into mitosis indicates that active Cdc2 is accumulating in the nucleus under these conditions. Disruption of the Cdc25C regulatory pathway can explain how Cdc2 becomes activated but does not address how active Cdc2 then accumulates in the nucleus. Throughout interphase and during the cellular response to DNA damage, Cdc2-cyclin B1 complexes shuttle between the nucleus and the cytoplasm (32-34). The apparent static cytoplasmic localization of Cdc2-cyclin B1 complexes is due to a nuclear export sequence in cyclin B1 that facilitates efficient nuclear export of these complexes. Cyclin B1 NES function is regulated by phosphorylation, and therefore kinases in the pathway regulating cyclin B1 NES function could also be potential targets of UCN-01 (33, 36). Finally, although UCN-01 does not directly inhibit the kinase activity of Wee1, it may interface with upstream regulators of Wee1 and thereby inhibit the Wee1 regulatory pathway (4, 60).

The p53 tumor suppressor is essential for DNA-damaged cells to arrest at the G₁ checkpoint (61, 62). Mutations in p53, a common occurrence in human cancer, abolish this response and in turn leave cancer cells vulnerable to abrogation of the last remaining barrier protecting them from the cytotoxicity of DNA-damaging agents, the G₂ checkpoint. Drugs designed to abrogate G₂ checkpoint function by inhibiting the function of the Chk1 kinase could improve the killing of p53-defective tumors and as such exhibit broad utilization in cancer chemotherapeutic and radiotherapy regimens (63). Indeed, observations that cancer cells deficient in p53 tumor suppressor function are more vulnerable to G₂ checkpoint abrogation (1, 64, 65) suggest this strategy might prove selective to cancer cells.

	ACKNOWLEDGEMENTS

We thank Jill Johnson for the UCN-01. We are also grateful to Dayana Krawchuk and Kimberly Rucker for technical assistance. We thank Geoffrey Uy for preparing pEGFP-Cdc25C and pEGFPC-Cdc25C(S216A).

	FOOTNOTES

^* This work was supported in part by a grant from the American Heart Association, Heartland Affiliate (to P. R. G.), and the National Institutes of Health (to H.  P.  W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Current address: Agouron Pharmaceuticals, Inc., 3565 General Atomics Ct., San Diego, CA 92121.

Investigator of the Howard Hughes Medical Institute. To whom correspondence should be addressed: Dept. of Cell Biology and Physiology, Howard Hughes Medical Institute, Washington University School of Medicine, Box 8228, 660 South Euclid Ave., St. Louis, MO 63110.

² P. R. Graves and H. Piwnica-Worms, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: NES, nuclear export signal; GST, glutathione S-transferase; PCR, polymerase chain reaction; ATM, ataxia telangiectasia-mutated; DTT, dithiothreitol; PBS, phosphate-buffered saline; RACE, rapid amplification of cDNA ends; GFP, green fluorescent protein; Gy, gray.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. Zhang, Z. Yan, C. L. Painter, Q. Zhang, E. Chen, M. E. Arango, K. Kuszpit, K. Zasadny, M. Hallin, J. Hallin, et al. PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts Clin. Cancer Res., July 15, 2009; 15(14): 4630 - 4640. [Abstract] [Full Text] [PDF]

				M. Y. Zhao, A. Auerbach, A. M. D'Costa, A. P. Rapoport, A. M. Burger, E. A. Sausville, S. A. Stass, F. Jiang, A. M. Sands, N. Aguilera, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy Clin. Cancer Res., March 1, 2009; 15(5): 1708 - 1720. [Abstract] [Full Text] [PDF]

				A. N. Tse, T. N. Sheikh, H. Alan, T.-C. Chou, and G. K. Schwartz 90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1 Mol. Pharmacol., January 1, 2009; 75(1): 124 - 133. [Abstract] [Full Text] [PDF]

				C. Marminon, F. Anizon, P. Moreau, B. Pfeiffer, A. Pierre, R. M. Golsteyn, P. Peixoto, M.-P. Hildebrand, M.-H. David-Cordonnier, O. Lozach, et al. Rebeccamycin Derivatives as Dual DNA-Damaging Agents and Potent Checkpoint Kinase 1 Inhibitors Mol. Pharmacol., December 1, 2008; 74(6): 1620 - 1629. [Abstract] [Full Text] [PDF]

				C. M. Lovly, L. Yan, C. E. Ryan, S. Takada, and H. Piwnica-Worms Regulation of Chk2 Ubiquitination and Signaling through Autophosphorylation of Serine 379 Mol. Cell. Biol., October 1, 2008; 28(19): 5874 - 5885. [Abstract] [Full Text] [PDF]

				Y. Dai, S. Chen, X.-Y. Pei, J. A. Almenara, L. B. Kramer, C. A. Venditti, P. Dent, and S. Grant Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells Blood, September 15, 2008; 112(6): 2439 - 2449. [Abstract] [Full Text] [PDF]

				S. D. Zabludoff, C. Deng, M. R. Grondine, A. M. Sheehy, S. Ashwell, B. L. Caleb, S. Green, H. R. Haye, C. L. Horn, J. W. Janetka, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther., September 1, 2008; 7(9): 2955 - 2966. [Abstract] [Full Text] [PDF]

				S. Ashwell and S. Zabludoff DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy Clin. Cancer Res., July 1, 2008; 14(13): 4032 - 4037. [Abstract] [Full Text] [PDF]

				L. Gall, D. Le Bourhis, S. Ruffini, C. Boulesteix, and X. Vignon Unexpected nuclear localization of Cdc25C in bovine oocytes, early embryos, and nuclear-transferred embryos Reproduction, April 1, 2008; 135(4): 431 - 438. [Abstract] [Full Text] [PDF]

				S. Ramalingam, G. Natarajan, C. Schafer, D. Subramaniam, R. May, I. Ramachandran, L. Queimado, C. W. Houchen, and S. Anant Novel intestinal splice variants of RNA-binding protein CUGBP2: isoform-specific effects on mitotic catastrophe Am J Physiol Gastrointest Liver Physiol, April 1, 2008; 294(4): G971 - G981. [Abstract] [Full Text] [PDF]

				S. Huard, R. T. Elder, D. Liang, G. Li, and R. Y. Zhao Human Immunodeficiency Virus Type 1 Vpr Induces Cell Cycle G2 Arrest through Srk1/MK2-Mediated Phosphorylation of Cdc25 J. Virol., March 15, 2008; 82(6): 2904 - 2917. [Abstract] [Full Text] [PDF]

				H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629. [Abstract] [Full Text] [PDF]

				A. A. Levesque, A. A. Fanous, A. Poh, and A. Eastman Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest Mol. Cancer Ther., February 1, 2008; 7(2): 252 - 262. [Abstract] [Full Text] [PDF]

				J. A. Seiler, C. Conti, A. Syed, M. I. Aladjem, and Y. Pommier The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses Mol. Cell. Biol., August 15, 2007; 27(16): 5806 - 5818. [Abstract] [Full Text] [PDF]

				L. Verlinden, I. Vanden Bempt, G. Eelen, M. Drijkoningen, I. Verlinden, K. Marchal, C. De Wolf-Peeters, M.-R. Christiaens, L. Michiels, R. Bouillon, et al. The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast Carcinomas Cancer Res., July 15, 2007; 67(14): 6574 - 6581. [Abstract] [Full Text] [PDF]

				Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation Blood, May 15, 2007; 109(10): 4415 - 4423. [Abstract] [Full Text] [PDF]

				L. Guo, X. Liu, K. Nishikawa, and W. Plunkett Inhibition of topoisomerase II{alpha} and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials Mol. Cancer Ther., May 1, 2007; 6(5): 1501 - 1508. [Abstract] [Full Text] [PDF]

				M. J. Edelman, K. S. Bauer Jr., S. Wu, R. Smith, S. Bisacia, and J. Dancey Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2667 - 2674. [Abstract] [Full Text] [PDF]

				D. Wilsker and F. Bunz Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol. Cancer Ther., April 1, 2007; 6(4): 1406 - 1413. [Abstract] [Full Text] [PDF]

				A. N. Tse, R. Carvajal, and G. K. Schwartz Targeting Checkpoint Kinase 1 in Cancer Therapeutics Clin. Cancer Res., April 1, 2007; 13(7): 1955 - 1960. [Abstract] [Full Text] [PDF]

				A. N. Tse, K. G. Rendahl, T. Sheikh, H. Cheema, K. Aardalen, M. Embry, S. Ma, E. J. Moler, Z. J. Ni, D. E. Lopes de Menezes, et al. CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo Clin. Cancer Res., January 15, 2007; 13(2): 591 - 602. [Abstract] [Full Text] [PDF]

				C. Vogel, C. Hager, and H. Bastians Mechanisms of Mitotic Cell Death Induced by Chemotherapy-Mediated G2 Checkpoint Abrogation Cancer Res., January 1, 2007; 67(1): 339 - 345. [Abstract] [Full Text] [PDF]

				A. A. Levesque and A. Eastman p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis, January 1, 2007; 28(1): 13 - 20. [Abstract] [Full Text] [PDF]

				M. Kedde, C. le Sage, A. Duursma, E. Zlotorynski, B. van Leeuwen, W. Nijkamp, R. Beijersbergen, and R. Agami Telomerase-independent Regulation of ATR by Human Telomerase RNA J. Biol. Chem., December 29, 2006; 281(52): 40503 - 40514. [Abstract] [Full Text] [PDF]

				O. Sapora and B. Di Carlo Cell signalling mechanisms and the control of cell life and death Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 210 - 220. [Full Text] [PDF]

				X.-Y. Pei, W. Li, Y. Dai, P. Dent, and S. Grant Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells Mol. Pharmacol., December 1, 2006; 70(6): 1965 - 1973. [Abstract] [Full Text] [PDF]

				B. Jaklevic, L. Uyetake, W. Lemstra, J. Chang, W. Leary, A. Edwards, S. Vidwans, O. Sibon, and T. Tin Su Contribution of Growth and Cell Cycle Checkpoints to Radiation Survival in Drosophila Genetics, December 1, 2006; 174(4): 1963 - 1972. [Abstract] [Full Text] [PDF]

				V. Leung-Pineda, C. E. Ryan, and H. Piwnica-Worms Phosphorylation of Chk1 by ATR Is Antagonized by a Chk1-Regulated Protein Phosphatase 2A Circuit Mol. Cell. Biol., October 15, 2006; 26(20): 7529 - 7538. [Abstract] [Full Text] [PDF]

				E. Schmitt, R. Boutros, C. Froment, B. Monsarrat, B. Ducommun, and C. Dozier CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage J. Cell Sci., October 15, 2006; 119(20): 4269 - 4275. [Abstract] [Full Text] [PDF]

				H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823. [Abstract] [Full Text] [PDF]

				C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release J Biomol Screen, October 1, 2006; 11(7): 792 - 806. [Abstract] [PDF]

				K. M. Comess, J. D. Trumbull, C. Park, Z. Chen, R. A. Judge, M. J. Voorbach, M. Coen, L. Gao, H. Tang, P. Kovar, et al. Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1 J Biomol Screen, October 1, 2006; 11(7): 755 - 764. [Abstract] [PDF]

				K. Liang, Y. Lu, X. Li, X. Zeng, R. I. Glazer, G. B. Mills, and Z. Fan Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine Mol. Pharmacol., September 1, 2006; 70(3): 1045 - 1052. [Abstract] [Full Text] [PDF]

				J.-M. Yun, M.-H. Kweon, H. Kwon, J.-K. Hwang, and H. Mukhtar Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145 Carcinogenesis, July 1, 2006; 27(7): 1454 - 1464. [Abstract] [Full Text] [PDF]

				B. Bugler, M. Quaranta, B. Aressy, M.-C. Brezak, G. Prevost, and B. Ducommun Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol. Cancer Ther., June 1, 2006; 5(6): 1446 - 1451. [Abstract] [Full Text] [PDF]

				E. Petermann, A. Maya-Mendoza, G. Zachos, D. A. F. Gillespie, D. A. Jackson, and K. W. Caldecott Chk1 Requirement for High Global Rates of Replication Fork Progression during Normal Vertebrate S Phase Mol. Cell. Biol., April 15, 2006; 26(8): 3319 - 3326. [Abstract] [Full Text] [PDF]

				M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF]

				R. Rossi, M. R. Lidonnici, S. Soza, G. Biamonti, and A. Montecucco The Dispersal of Replication Proteins after Etoposide Treatment Requires the Cooperation of Nbs1 with the Ataxia Telangiectasia Rad3-Related/Chk1 Pathway Cancer Res., February 1, 2006; 66(3): 1675 - 1683. [Abstract] [Full Text] [PDF]

				S. J. Hotte, A. Oza, E. W. Winquist, M. Moore, E. X. Chen, S. Brown, G. R. Pond, J. E. Dancey, and H. W. Hirte Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study Ann. Onc., February 1, 2006; 17(2): 334 - 340. [Abstract] [Full Text] [PDF]

				C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]

				H. Niida and M. Nakanishi DNA damage checkpoints in mammals Mutagenesis, January 1, 2006; 21(1): 3 - 9. [Abstract] [Full Text] [PDF]

				G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]

				J. Tabernero, T. Macarulla, F. J. Ramos, and J. Baselga Novel targeted therapies in the treatment of gastric and esophageal cancer Ann. Onc., November 1, 2005; 16(11): 1740 - 1748. [Abstract] [Full Text] [PDF]

				C. A. L. Clarke, L. N. Bennett, and P. R. Clarke Cleavage of Claspin by Caspase-7 during Apoptosis Inhibits the Chk1 Pathway J. Biol. Chem., October 21, 2005; 280(42): 35337 - 35345. [Abstract] [Full Text] [PDF]

				D. I. Beardsley, W.-J. Kim, and K. D. Brown N-Methyl-N'-nitro-N-nitrosoguanidine Activates Cell-Cycle Arrest through Distinct Mechanisms Activated in a Dose-Dependent Manner Mol. Pharmacol., October 1, 2005; 68(4): 1049 - 1060. [Abstract] [Full Text] [PDF]

				L. Gao, L. Zhang, J. Hu, F. Li, Y. Shao, D. Zhao, D. V. Kalvakolanu, D. J. Kopecko, X. Zhao, and D.-Q. Xu Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivo Clin. Cancer Res., September 1, 2005; 11(17): 6333 - 6341. [Abstract] [Full Text] [PDF]

				X. Liu, Y. Guo, Y. Li, Y. Jiang, S. Chubb, A. Azuma, P. Huang, A. Matsuda, W. Hittelman, and W. Plunkett Molecular Basis for G2 Arrest Induced by 2'-C-Cyano-2'-Deoxy-1-{beta}-D-Arabino-Pentofuranosylcytosine and Consequences of Checkpoint Abrogation Cancer Res., August 1, 2005; 65(15): 6874 - 6881. [Abstract] [Full Text] [PDF]

				G. K. Schwartz Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508. [Abstract] [Full Text] [PDF]

				M. Ozen and M. Ittmann Increased Expression and Activity of CDC25C Phosphatase and an Alternatively Spliced Variant in Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4701 - 4706. [Abstract] [Full Text] [PDF]

				P. N. Lara Jr, P. C. Mack, T. Synold, P. Frankel, J. Longmate, P. H. Gumerlock, J. H. Doroshow, and D. R. Gandara The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial Clin. Cancer Res., June 15, 2005; 11(12): 4444 - 4450. [Abstract] [Full Text] [PDF]

				X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., June 15, 2005; 11(12): 4589 - 4600. [Abstract] [Full Text] [PDF]

				K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons J. Biol. Chem., April 8, 2005; 280(14): 14349 - 14355. [Abstract] [Full Text] [PDF]

				A. M. Ferguson, L. S. White, P. J. Donovan, and H. Piwnica-Worms Normal Cell Cycle and Checkpoint Responses in Mice and Cells Lacking Cdc25B and Cdc25C Protein Phosphatases Mol. Cell. Biol., April 1, 2005; 25(7): 2853 - 2860. [Abstract] [Full Text] [PDF]

				R. P. Singh, P. Agrawal, D. Yim, C. Agarwal, and R. Agarwal Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate Carcinogenesis, April 1, 2005; 26(4): 845 - 854. [Abstract] [Full Text] [PDF]

				E. A. Sausville Indifferently Pursued or Unowned Drugs: Who Should Lead Where Companies Do Not Tread? J. Clin. Oncol., March 20, 2005; 23(9): 1796 - 1798. [Full Text] [PDF]

				J. Kortmansky, M. A. Shah, A. Kaubisch, A. Weyerbacher, S. Yi, W. Tong, R. Sowers, M. Gonen, E. O'Reilly, N. Kemeny, et al. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors J. Clin. Oncol., March 20, 2005; 23(9): 1875 - 1884. [Abstract] [Full Text] [PDF]

				M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470. [Abstract] [Full Text] [PDF]

				A. W. Adamson, D. I. Beardsley, W.-J. Kim, Y. Gao, R. Baskaran, and K. D. Brown Methylator-induced, Mismatch Repair-dependent G2 Arrest Is Activated through Chk1 and Chk2 Mol. Biol. Cell, March 1, 2005; 16(3): 1513 - 1526. [Abstract] [Full Text] [PDF]

				Y. Dai, M. Rahmani, X.-Y. Pei, P. Khanna, S. I. Han, C. Mitchell, P. Dent, and S. Grant Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK Blood, February 15, 2005; 105(4): 1706 - 1716. [Abstract] [Full Text] [PDF]

				S. L. Maude and G. H. Enders Cdk Inhibition in Human Cells Compromises Chk1 Function and Activates a DNA Damage Response Cancer Res., February 1, 2005; 65(3): 780 - 786. [Abstract] [Full Text] [PDF]

				G. Zachos, M. D. Rainey, and D. A. F. Gillespie Chk1-Dependent S-M Checkpoint Delay in Vertebrate Cells Is Linked to Maintenance of Viable Replication Structures Mol. Cell. Biol., January 15, 2005; 25(2): 563 - 574. [Abstract] [Full Text] [PDF]

				R. G. Syljuasen, C. S. Sorensen, J. Nylandsted, C. Lukas, J. Lukas, and J. Bartek Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation Cancer Res., December 15, 2004; 64(24): 9035 - 9040. [Abstract] [Full Text] [PDF]

				M. Urist, T. Tanaka, M. V. Poyurovsky, and C. Prives p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2 Genes & Dev., December 15, 2004; 18(24): 3041 - 3054. [Abstract] [Full Text] [PDF]

				S. B. Kondapaka, M. Zarnowski, D. R. Yver, E. A. Sausville, and S. W. Cushman 7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation: A Basis for Decreased Insulin-Stimulated Glucose Transport Clin. Cancer Res., November 1, 2004; 10(21): 7192 - 7198. [Abstract] [Full Text] [PDF]

				X. Zhang, J. Succi, Z. Feng, S. Prithivirajsingh, M. D. Story, and R. J. Legerski Artemis Is a Phosphorylation Target of ATM and ATR and Is Involved in the G2/M DNA Damage Checkpoint Response Mol. Cell. Biol., October 15, 2004; 24(20): 9207 - 9220. [Abstract] [Full Text] [PDF]

				X. Jiang, B. Zhao, R. Britton, L. Y. Lim, D. Leong, J. S. Sanghera, B.-B. S. Zhou, E. Piers, R. J. Andersen, and M. Roberge Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide Mol. Cancer Ther., October 1, 2004; 3(10): 1221 - 1227. [Abstract] [Full Text] [PDF]

				J. Wang, T. Wiltshire, Y. Wang, C. Mikell, J. Burks, C. Cunningham, E. S. Van Laar, S. J. Waters, E. Reed, and W. Wang ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven J. Biol. Chem., September 17, 2004; 279(38): 39584 - 39592. [Abstract] [Full Text] [PDF]

				A. N. Tse and G. K. Schwartz Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe Cancer Res., September 15, 2004; 64(18): 6635 - 6644. [Abstract] [Full Text] [PDF]

				K. E. Luker, M. C. P. Smith, G. D. Luker, S. T. Gammon, H. Piwnica-Worms, and D. Piwnica-Worms Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals PNAS, August 17, 2004; 101(33): 12288 - 12293. [Abstract] [Full Text] [PDF]

				G. P. Dasmahapatra, P. Didolkar, M. C. Alley, S. Ghosh, E. A. Sausville, and K. K. Roy In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines Clin. Cancer Res., August 1, 2004; 10(15): 5242 - 5252. [Abstract] [Full Text] [PDF]

				T. Kondo, M. Kobayashi, J. Tanaka, A. Yokoyama, S. Suzuki, N. Kato, M. Onozawa, K. Chiba, S. Hashino, M. Imamura, et al. Rapid Degradation of Cdt1 upon UV-induced DNA Damage Is Mediated by SCFSkp2 Complex J. Biol. Chem., June 25, 2004; 279(26): 27315 - 27319. [Abstract] [Full Text] [PDF]

				L. Stojic, N. Mojas, P. Cejka, M. di Pietro, S. Ferrari, G. Marra, and J. Jiricny Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase Genes & Dev., June 1, 2004; 18(11): 1331 - 1344. [Abstract] [Full Text] [PDF]

				D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647. [Abstract] [Full Text] [PDF]

				T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther., April 1, 2004; 3(4): 513 - 519. [Abstract] [Full Text] [PDF]

				Y. Dai, X.-Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells Blood, April 1, 2004; 103(7): 2761 - 2770. [Abstract] [Full Text] [PDF]

				X. Meng, Y. Yuan, A. Maestas, and Z. Shen Recovery from DNA Damage-induced G2 Arrest Requires Actin-binding Protein Filamin-A/Actin-binding Protein 280 J. Biol. Chem., February 13, 2004; 279(7): 6098 - 6105. [Abstract] [Full Text] [PDF]

				S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577. [Abstract] [Full Text] [PDF]

				S. Gonzalez, C. Prives, and C. Cordon-Cardo p73{alpha} Regulation by Chk1 in Response to DNA Damage Mol. Cell. Biol., November 15, 2003; 23(22): 8161 - 8171. [Abstract] [Full Text] [PDF]

				M.-S. Chen, C. E. Ryan, and H. Piwnica-Worms Chk1 Kinase Negatively Regulates Mitotic Function of Cdc25A Phosphatase through 14-3-3 Binding Mol. Cell. Biol., November 1, 2003; 23(21): 7488 - 7497. [Abstract] [Full Text] [PDF]

				J. R. A. Hutchins, D. Dikovskaya, and P. R. Clarke Regulation of Cdc2/Cyclin B Activation in Xenopus Egg Extracts via Inhibitory Phosphorylation of Cdc25C Phosphatase by Ca2+/Calmodium-dependent Kinase II Mol. Biol. Cell, October 1, 2003; 14(10): 4003 - 4014. [Abstract] [Full Text] [PDF]

				W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways Blood, September 1, 2003; 102(5): 1824 - 1832. [Abstract] [Full Text] [PDF]

				D. M. Goudelock, K. Jiang, E. Pereira, B. Russell, and Y. Sanchez Regulatory Interactions between the Checkpoint Kinase Chk1 and the Proteins of the DNA-dependent Protein Kinase Complex J. Biol. Chem., August 8, 2003; 278(32): 29940 - 29947. [Abstract] [Full Text] [PDF]

				S. Lambert, S. J. Mason, L. J. Barber, J. A. Hartley, J. A. Pearce, A. M. Carr, and P. J. McHugh Schizosaccharomyces pombe Checkpoint Response to DNA Interstrand Cross-Links Mol. Cell. Biol., July 1, 2003; 23(13): 4728 - 4737. [Abstract] [Full Text] [PDF]

				J. K. Schwarz, C. M. Lovly, and H. Piwnica-Worms Regulation of the Chk2 Protein Kinase by Oligomerization-Mediated cis- and trans-Phosphorylation Mol. Cancer Res., June 1, 2003; 1(8): 598 - 609. [Abstract] [Full Text] [PDF]

				R. M. Douglas and G. G. Haddad Genetic Models in Applied Physiology: Invited Review: Effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest J Appl Physiol, May 1, 2003; 94(5): 2068 - 2083. [Abstract] [Full Text] [PDF]

				M. Gatei, K. Sloper, C. Sorensen, R. Syljuasen, J. Falck, K. Hobson, K. Savage, J. Lukas, B.-B. Zhou, J. Bartek, et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation J. Biol. Chem., April 18, 2003; 278(17): 14806 - 14811. [Abstract] [Full Text] [PDF]

				C. Yu, M. Rahmani, Y. Dai, D. Conrad, G. Krystal, P. Dent, and S. Grant The Lethal Effects of Pharmacological Cyclin-dependent Kinase Inhibitors in Human Leukemia Cells Proceed through a Phosphatidylinositol 3-Kinase/Akt-dependent Process Cancer Res., April 15, 2003; 63(8): 1822 - 1833. [Abstract] [Full Text] [PDF]

				R. S. Weiss, P. Leder, and C. Vaziri Critical Role for Mouse Hus1 in an S-Phase DNA Damage Cell Cycle Checkpoint Mol. Cell. Biol., February 1, 2003; 23(3): 791 - 803. [Abstract] [Full Text]

				H. Miao, J. A. Seiler, and W. C. Burhans Regulation of Cellular and SV40 Virus Origins of Replication by Chk1-dependent Intrinsic and UVC Radiation-induced Checkpoints J. Biol. Chem., January 31, 2003; 278(6): 4295 - 4304. [Abstract] [Full Text] [PDF]

				E. A. Kohn, C. J. Yoo, and A. Eastman The Protein Kinase C Inhibitor Go6976 Is a Potent Inhibitor of DNA Damage-induced S and G2 Cell Cycle Checkpoints Cancer Res., January 1, 2003; 63(1): 31 - 35. [Abstract] [Full Text] [PDF]

				S. Wang, Z. Wang, and S. Grant Bryostatin 1 and UCN-01 Potentiate 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms Mol. Pharmacol., January 1, 2003; 63(1): 232 - 242. [Abstract] [Full Text] [PDF]

				E. Okubo, J. M. Lehman, and T. D. Friedrich Negative Regulation of Mitotic Promoting Factor by the Checkpoint Kinase Chk1 in Simian Virus 40 Lytic Infection J. Virol., December 20, 2002; 77(2): 1257 - 1267. [Abstract] [Full Text] [PDF]

				T. P. Heffernan, D. A. Simpson, A. R. Frank, A. N. Heinloth, R. S. Paules, M. Cordeiro-Stone, and W. K. Kaufmann An ATR- and Chk1-Dependent S Checkpoint Inhibits Replicon Initiation following UVC-Induced DNA Damage Mol. Cell. Biol., December 15, 2002; 22(24): 8552 - 8561. [Abstract] [Full Text] [PDF]

				B. Zhao, M. J. Bower, P. J. McDevitt, H. Zhao, S. T. Davis, K. O. Johanson, S. M. Green, N. O. Concha, and B.-B. S. Zhou Structural Basis for Chk1 Inhibition by UCN-01 J. Biol. Chem., November 22, 2002; 277(48): 46609 - 46615. [Abstract] [Full Text] [PDF]

				H. Zhao, J. L. Watkins, and H. Piwnica-Worms Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints PNAS, November 12, 2002; 99(23): 14795 - 14800. [Abstract] [Full Text] [PDF]

				X. Wang, G. C. Li, G. Iliakis, and Y. Wang Ku Affects the CHK1-dependent G2 Checkpoint after Ionizing Radiation Cancer Res., November 1, 2002; 62(21): 6031 - 6034. [Abstract] [Full Text] [PDF]

				A. K. Tyagi, R. P. Singh, C. Agarwal, D. C. F. Chan, and R. Agarwal Silibinin Strongly Synergizes Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth Inhibition, G2-M Arrest, and Apoptosis Clin. Cancer Res., November 1, 2002; 8(11): 3512 - 3519. [Abstract] [Full Text] [PDF]

				V. Patel, T. Lahusen, C. Leethanakul, T. Igishi, M. Kremer, L. Quintanilla-Martinez, J. F. Ensley, E. A. Sausville, J. S. Gutkind, and A. M. Senderowicz Antitumor Activity of UCN-01 in Carcinomas of the Head and Neck Is Associated with Altered Expression of Cyclin D3 and p27KIP1 Clin. Cancer Res., November 1, 2002; 8(11): 3549 - 3560. [Abstract] [Full Text] [PDF]

				Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism Blood, October 16, 2002; 100(9): 3333 - 3343. [Abstract] [Full Text] [PDF]

				Q. Yu, J. La Rose, H. Zhang, H. Takemura, K. W. Kohn, and Y. Pommier UCN-01 Inhibits p53 Up-Regulation and Abrogates {gamma}-Radiation-induced G2-M Checkpoint Independently of p53 by Targeting Both of the Checkpoint Kinases, Chk2 and Chk1 Cancer Res., October 15, 2002; 62(20): 5743 - 5748. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graves, P. R. Articles by Piwnica-Worms, H. Search for Related Content PubMed PubMed Citation Articles by Graves, P. R. Articles by Piwnica-Worms, H. Social Bookmarking                      What's this?